APIX Biosciences

About APIX Biosciences

APIX Biosciences is a preclinical-stage biotechnology company focused on developing therapies for neurodegenerative and inflammatory diseases. The company was founded in 2021 by a team of scientists with deep expertise in drug discovery and development. Co-founder and CEO, Dr. Johannes Zuegg, has a background in bioinformatics and computational drug design, having co-founded several other biotech companies including Anatara Lifesciences. The company's core technology revolves around its APix platform, which discovers and develops small molecule drugs that target and modulate disease-causing proteins. This platform enables the development of a pipeline of drug candidates aimed at treating conditions such as Alzheimer's, Parkinson's, and other inflammatory disorders.

The company's business model is centered on advancing its drug candidates through preclinical and clinical development, with the ultimate goal of partnering with larger pharmaceutical companies for late-stage development and commercialization. APIX Biosciences operates in the biotechnology and pharmaceutical market, specifically targeting the high unmet medical need in neurodegenerative diseases. The lead program focuses on developing novel treatments by modulating specific biological pathways implicated in disease progression. By leveraging its proprietary platform, the company aims to create a new class of therapeutics with improved efficacy and safety profiles compared to existing treatments. APIX Biosciences is backed by venture capital funding, which supports its research and development activities.